Contact through OTT webpage does not guarantee a second opinion visit at the site nor a slot in the specific clinical trial of interest.

Clinical trial details

A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies

Identifier

GRWD5769-ST-01

Sponsor

GREYWOLF THERAPEUTICS

Principal Investigator

ELENA GARRALDA CABANAS

Service

Oncology

Study details

Tumor type: ALL SOLID TUMORS
Stage: Advanced
Main Investigational Agent : Targeted therapy
Phase: I
Randomization: Non-randomized

Molecular details

Biomarker: Not applicable
Biomarker criteria: Not applicable
Prescreening: Not applicable
Additional study population requirements: GRWD5769 (an inhibitor of the endoplasmic reticulum aminopeptidase 1 [ERAP1] enzyme)

Drug details

Arm A: GRWD5769
Arm B: GRWD5769 + Cemiplimab

Links

Clinical Trials GOV (NCT identifier): NL
EU Clinical Trials Register (eudraCT Identifier): Not applicable